As reported previously (Sep 2018) Israel’s Orasis has developed CSF-1 (eye drops) to treat presbyopia – age-related far-sightedness. Results of Phase 2b trials of CSF-1 showed “significant improvement”, together with “exceptional safety and tolerability”.

https://www.orasis-pharma.com/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/